About Grifols
Grifols news and updates
Schroeder left Grifols Canada Therapeutics Inc as CEO on Jan 1st 14'.
Schroeder comes to the neurovascular device maker from Grifols Diagnostic Solutions, where he has been CEO since 2014.
Jan 1, 2020 | ocbj.comGrifols Canada Therapeutics Inc launched Procleix Panther System on Oct 1st 19'.
Grifols launched the Procleix Panther System last October in countries accepting the CE mark.
Jan 1, 2020 | medicaldevice-network.comGrifols Canada Therapeutics Inc launches installation in North America of the DG Reader Net semi-automated analyser
Grifols, a developer of plasma-derived therapies and diagnostic solutions, announced its first-ever installation in North America of the DG Reader Net semi-automated analyser, used to facilitate pre-transfusion blood type compatibility testing.
Jan 1, 2021 | med-technews.comGrifols Canada Therapeutics Inc partners with Feeding America, Inc
- In the U.S., 38 million people face hunger, including 12 million children BARCELONA, Spain, March 2, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the health and well-being of people, today announced it is partnering with Feeding America, the nation's largest domestic hunger-relief organization, to help "box out hunger" by collecting nonperishable food and raising money for local member food banks across the country.
Jan 1, 2022 | yahoo.comGrifols Canada Therapeutics Inc partners with Feeding America
In the U.S., 38 million people face hunger, including 12 million children Barcelona, Spain, March 2, 2022 – Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the health and well-being of people, today announced it is partnering with Feeding America, the nation’s largest domestic hunger-relief organization, to help “box out hunger” by collecting nonperishable food and raising money for local member food banks across the country.
Jan 1, 2022 | grifols.comGrifols Canada Therapeutics Inc launches installation in North America of the DG Reader Net semi-automated analyser
Grifols, a developer of plasma-derived therapies and diagnostic solutions, announced its first-ever installation in North America of the DG Reader Net semi-automated analyser, used to facilitate pre-transfusion blood type compatibility testing.
Jan 1, 2022 | med-technews.comGrifols Canada Therapeutics Inc launches HyperHEP B
Grifols announced the US launch of HyperHEP B ® for hepatitis B postexposure prophylaxis.
Jan 1, 2021 | empr.comGrifols Canada Therapeutics Inc acquires Tiancheng for $1.15M
Grifols has agreed to acquire the entire share capital of Tiancheng ( Germany ) Pharmaceutical Holdings AG for EUR 1,091 million.
Jan 1, 2022 | prnewswire.comGrifols Canada Therapeutics Inc launches flexible bag forma ALBUTEIN FlexBag
For instance, Grifols expanded its albumin portfolio with the launch of flexible bag forma ALBUTEIN FlexBag that offers a convenient, easy-to-use format to healthcare professionals.
Jan 1, 2022 | globenewswire.comGrifols Canada Therapeutics Inc is developing plasma-derived COVID-19 therapeutic
Grifols has entered a formal collaboration with the US Biomedical Advanced Research Development Authority (BARDA), Food and Drug Administration (FDA) and other Federal public health agencies to develop a plasma-derived COVID-19 therapeutic.
Jan 1, 2020 | drugtargetreview.comGrifols Canada Therapeutics Inc invests into assets : plasma fractionation facility and two purification facilities in the amount of $460M
Grifols, one of world's top producers of plasma-derived medicines, has entered an agreement to acquire GC Pharma Group’s Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for $460 million.
Jan 1, 2020 | contractpharma.comGrifols Canada Therapeutics Inc acquires GigaGen Inc
Grifols's acquisition of GigaGen comes as the startup's Covid-19 antibody drug is set to start Phase 1 testing.
Jan 1, 2021 | medcitynews.comGrifols Canada Therapeutics Inc partnered with Direct Relief International on Jun 1st 21'.
Earlier this year Grifols, in partnership with Direct Relief, donated six million international units (IU) of HyperHEP B S/D to various underserved countries around the world.
Jan 1, 2021 | prnewswire.comGrifols Canada Therapeutics Inc acquired Talecris Biotherapeutics, Inc. on Jan 1st 11'.
By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 77% of sales in 2021.
Jan 1, 2022 | investorsobserver.comCanadian Blood Services partnered with Grifols Canada Therapeutics Inc on Aug 8th 22'.
Last week news broke that Canadian Blood Services (CBS) is seeking to partner with Grifols, the world’s largest blood plasma producer, to ramp up plasma collection in Canada, primarily through compensating donors for their donation.
Aug 3, 2022 | consumerchoicecenter.orgGrifols Canada Therapeutics Inc hired Steven F. Mayer as Executive Chairperson on Oct 3rd 22'.
Steven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L. P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive Chairperson BARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced today changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairperson while Mr. Victor Grifols Roura retired as Chairperson and was named Chairperson of Honor.
Oct 2, 2022 | ksnt.comGrifols Canada Therapeutics Inc expands offices in Dublin, Ireland
Pharma company Grifols is expanding its presence in Dublin, with the inauguration of a new specialist plant and a plan to create up to 200 jobs.
Oct 19, 2022 | siliconrepublic.com